BGI-9004 / BridGene Biosci - LARVOL DELTA

BridGene Biosciences to Present at Hippo Pathway Targeted Drug Development Summit (PRNewswire) - "BridGene Biosciences...announced that Wolf Wiedemeyer, Ph.D., head of biology at BridGene, will be giving a presentation...at the 2nd Annual Hippo Pathway Targeted Drug Development Summit on May 24 in Boston....Dr. Wiedemeyer's presentation will provide a preclinical update on a lead covalent TEAD inhibitor, including in vivo efficacy, harnessing TEAD selectivity to expand into TEADi-responsive indications and exploring combination approaches with KRAS inhibitors, which have shown promising results in clinical trials for cancer."

Preclinical • Oncology

Preclinical characterization of BGI-9004, a covalent TEAD inhibitor with exceptional anti-cancer activity and combination potential (AACR 2023) - "These results suggest that inhibition of YAP/TAZ-TEAD signaling may improve the efficacy of KRAS-targeted therapy. Taken together, the covalent TEAD inhibitor BGI-9004 has demonstrated promising activity both as a single agent and in combination with other targeted agents, a favorable pharmacokinetic profile and high target selectivity in preclinical models, supporting its evaluation as a novel anti-cancer agent in clinical trials."

Preclinical • Lung Cancer • Mesothelioma • Oncology • Solid Tumor • KRAS • NF2 • TEAD1

BridGene Biosciences to Present Pre-Clinical Data of BGI-9004 at the AACR Annual Meeting 2023 (PRNewswire) - "BridGene Biosciences, Inc...announced that it will present a poster, titled 'Preclinical characterization of BGI-9004, a covalent TEAD inhibitor with exceptional anti-cancer activity and combination potential,' at the American Association for Cancer Research (AACR) Annual Meeting 2023 on April 18 in Orlando....'The covalent TEAD inhibitor BGI-9004 has demonstrated promising activity both as a single agent and in combination with other targeted agents, a favorable pharmacokinetic profile and high target selectivity in preclinical models, supporting its evaluation as a novel anti-cancer agent in clinical trials.'"

Preclinical • Oncology

Covalent pan-TEAD inhibitors for the treatment of cancers with Hippo pathway alterations (AACR-NCI-EORTC 2022) - "Our ultimate goal is to take our covalent TEAD inhibitor to the clinic for the treatment of cancers with Hippo pathway alterations, and as a potential combination agent in cancers with acquired drug resistance as a result of activated YAP/TAZ signaling. No"

Lung Cancer • Mesothelioma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • LATS1

BridGene Biosciences to Present Data from Two Preclinical Studies at 34th EORTC-NCI-AACR Symposium 2022 (PRNewswire) - "BridGene Biosciences, Inc...announced that two abstracts featuring the application of the company's proprietary chemoproteomic platform IMTAC™ and the company's leading program TEAD inhibitors, have been accepted for poster presentation and discussion sessions at the 34th (ENA 2022) European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI), and American Association for Cancer Research (AACR) Symposium, which is being held October 26-28, 2022, in Barcelona....ENA 2022 will feature experts in cancer drug development and translational research who facilitate in-depth scientific discussions on the latest developments in targets and drugs from pre-clinical and phase I settings."

Preclinical • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor